维A酸在皮肤病治疗中应用的进展

摘要/Abstract

摘要： 自20世纪以来,已知在正常上皮细胞增殖和分化中需要维生素A(VitA),如果缺乏VitA则引起上皮细胞癌变率增加,但治疗皮肤角化病时,治疗量即可引起不良反应。Karrer等^[1]1931年测出视黄醇(VitA)的结构式,并获得诺贝尔奖,12年后人工合成了VitA。为了寻找高效低毒的化合物,化学家们对VitA分子结构进行了改造,获得了多种VitA结构类似物,统称“retinoids”。国内文献曾译为“类视黄醇”、“类维生素甲”和“维甲酸”。由于它主要是维甲酸的衍生物,因此国内绝大多数作者均译为“维甲酸”,现称“维A酸”。1946年合成全反式维A酸(all-trans-retinoicacid,atRA)。

靳培英. 维A酸在皮肤病治疗中应用的进展[J]. 中华皮肤科杂志, 2000, 33(6): 448-451.doi:

. [J]. Chinese Journal of Dermatology, 2000, 33(6): 448-451.doi:

参考文献

1 Kligman AM. The growing importance of topical retinoids in clinical dermatology: a retrospective and prospective analysis. J Am Acad Dermatol,1998,39(2 Pt 3):S2-7.
2 Martin B Meunier C Montels D, et al. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol, 1998,139(Suppl 52):8-11.
3 Chandraratna RA. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol, 1997,37(2 Pt 3):S12-17.
4 Gollnick HP. Oral retinoids—efficacy and toxi-city in psoriasis. Br J Dermatol, 1996,135(Suppl 49):6-17.
5 Orfanos CE, Ehlert R, GollnicK H, et al. The retinoids. A review of their clinical pharmacology and therapeutic use. Drug, 1987,34:459-503.
6 Wiegand UW, Chou RC. Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol, 1998,39(2 Pt 3) :S25-33.
7 Stuttgen G. Historical perspectives of tretinoin. J Am Acad Dermatol, 1986,15:735-740.
8 Marks R. Early clinical development of tazaro-tene. Br J Dermatol, 1996,135(Suppl 49):26-31.
9 Craven NM, Griffiths CE. Topical retinoids and cutaneous biology. Clin Exp Dermatol, 1996,21:1-10.
10 Shroot B. Pharmacodynamics and pharmacoki-netics of topical adapalene. J Am Acad Dermatol, 1998,39(2 Pt 3):S17-24.
11 Rafal ES, Griffiths CE, Ditre CM, et al. Topical tretinoin (retinoic acid) treatment for liver spots associated with photodamage. N Engl J Med, 1992,326:368-374.
12 Welsh BM, Mason RS, Halliday GM. Topical all-trans retinoic acid augments ultraviolet radiation-induced increases in activated melanocyte numbers in mice. J Invest Dermatol, 1999,112:271-278.
13 Talwar HS, Griffiths CE, Fisher GJ et al. Differential regulation of tyrosinase activity in skin of white and black individuals in vivo by topical retinoic acid. J Invest Dermatol, 1993,100:800-805.
14 Bouclier M, Shroot B, Dionisius V, et al. A rapid and simple test system for the evaluation of the inhibitory activity of topical retinoids on cellotape stripping-induced ODC activity in the hairless rat.Dermatologica,1984,169:242-243.
15 Asselineau D, Cavey MT, Shroot B, et al. Control of epidermal differentiation by a retinoid analogue unable to bind to cytosolic retinoic acid-binding proteins (CRABP). J Invest Dermatol, 1992,98:128-134.
16 Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, et al. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol, 1994,30:581-590.
17 Verschoore M, Bouclier M, Czernielewski J, et al. Topical retinoids. Their uses in Dermatology. Dermatol Clin, 1993,11:107-115.
18 Webster GF.Topical tretinoin in acne therapy.J Am Acad Dermatol,1998,39:S38-44.
19 Verschoore M, Poncet M, Czernielewski J, et al. Adapalene 0.1% gel has low skin-irritation potential. J Am Acad Dermatol, 1997,36(6 Pt 2):S104-109.
20 Langner A, Stapor W, Donald AE, et al. Double-blind, placebo-controlled study of the efficacy and safety of isotretinoin cream (0.05% w/w and 0.1% w/w)with sunscreens in the treatment of mild to moderate acne vulgaris. J Dermatol Treat, 2000,11:7-14.
21 Marks R. The pathology of chronic solar damage and the effects of topical tretinoin. J Dermatol Treat, 1996,7(Suppl 2): S13-17.
22 Schwartz E, Mezick JA, Gendimenico GJ, et al. Treatment of steroid atrophy with topical tretinoin in the hairless mouse: a histologic, biochemical and immunochemical analysis. J Dermatol Treat, 1995,6:25-29.
23 Kang S. Photoaging and tretinoin. Dermatol Clin, 1998,16:357-364.
24 Kligman AM, Graham GF. Histological chan-ges in facial skin after daily application of tretinoin for 5 to 6 years. J Dermatol Treat, 1993,4:113-117.
25 Griffiths CE,Finkel LJ,Ditre CM,et al.To-pical tretinoin (retinoid acid) improves melasma.A vehicle-controlled,clinical trial.Br J Dermatol,1993,129:415-421.
26 Bulengo-Ransby SM, Griffiths CE, Kimbrou-gh-Green CK, et al. Topical tretinoin (retinoid acid) therapy for hyperpigmented lesions caus-ed by inflammation of the skin in black patients. N Engl J Med, 1993,328:1438-1443.
27 Griffiths CE, Goldfarb MT, Finkel LJ, et al. Topical tretinoin (retinoid acid) treatment of hyperpigmented lesions associated with photoaging in Chinese and Japanese patients: a vehicle controlled trial. J Am Acad Dermatol, 1994,30:76-84.
28 Stege H, Hofmann B, Ruzicka T, et al. Topical application of tazarotene in the treatment of nonerythrodermic lamellar ichthyosis. Arch Dermatol, 1998,134:640.
29 Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol, 1997,37:85-92.
30 Edwards KR, Burke WA. Treatment of localized discoid lupus erythematousus with tazaro-tene. J Am Acad Dermatol, 1999,41:1049-1050.
31 Bergfeld WF.Retinoids and hair growth.J Am Acad Dermatol,1998,39(2 Pt 3):S86-9.
32 Alirezai M,Dupuy P,Amblard P,et al.Cli-nical evaluation of topical isotretinoin in the treatment of actinic keratoses.J Am Acad Dermatol,1994,30:447-451.
33 Clucas A, Verschoore M, Sorba V, et al. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. J Am Acad Dermatol, 1997,36(6 Pt 2):S116-118.
34 Gilchrest BA. Treatment of photodamage with topical tretinoin: an overview. J Am Acad Dermatol, 1997,36(3 Pt 2):S27-36.
35 Roche Pharmaceuticals. Accutane(isotreti-noin). J Am Acad Dermatol, 1999,41:25A.
36 Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol, 1999,41(3 Pt 2):S7-12.